Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7604960: Transient protein expression methods

Share

Filing Information

Inventor(s) Guus Hateboer · Menzo J. E. Havenga · Ronald Vogels · Lennart Holterman ·
Assignee(s) Crucell Holland B.V. ·
Attorney/Agent(s) TraskBritt ·
Primary Examiner Stacy B Chen ·
Application Number US11809697
Filing date 06/01/2007
Issue date 10/20/2009
Prior Publication Data
Predicted expiration date 05/23/2020
Patent term adjustment 39
U.S. Classifications 435/691  · 424/233.1  · 435/455  · 435/320.1  ·
International Classifications C12N1500  · C12N15861  · C12P2106  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent application Ser. No. 11/592,409, filed Nov. 3, 2006 now U.S. Pat. No. 7,470,523, the contents of the entirety of which is incorporated by this reference, which is a divisional of U.S. patent application Ser. No. 10/234,007, filed Sep. 3, 2002, now U.S. Pat. No. 7,132,280, issued Nov. 7, 2006, the contents of the entirety of which, including its sequence listing, is incorporated by this reference, which is a divisional of U.S. patent application Ser. No. 09/549,463, filed Apr. 14, 2000, now U.S. Pat. No. 6,855,544, issued Feb. 15, 2005, the entire contents of which, including its sequence listing, is incorporated by this reference, which application claims priority under 35 U.S.C. Section 119(e) to Provisional Patent Application Ser. No. 60/129,452 filed Apr. 15, 1999.
20 Claims, 11 Drawings


Abstract

Described is a method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein the adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of the first region and the second region is required for adenoviral genome replication and/or adenovirus particle formation, b) propagating the adenoviral vector in a first type of complementing cells that express proteins from the first and from the second region of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, c) infecting a culture of a second type of complementing cells with the recombinant adenovirus particles, wherein the second type of complementing cells express protein from the first region of the adenovirus genome but not protein from the second region of the adenovirus genome, to produce the protein of interest, and d) harvesting the protein of interest.

Independent Claims | See all claims (20)

  1. 1. A method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein said recombinant adenoviral vector has deletions in the E1 and the E2A regions of the adenovirus genome, b) propagating said recombinant adenoviral vector in complementing cells that express adenoviral E1 protein and adenoviral E2A protein, to obtain recombinant adenovirus particles, c) infecting a culture of complementing cells that express adenoviral E1 protein, but not adenoviral E2A protein, with said recombinant adenovirus particles, to produce the protein of interest, and d) harvesting the protein of interest.
  2. 16. A method of producing a protein of interest, the method comprising: providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein said recombinant adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of said first second regions is required for adenoviral genome replication and/or adenovirus particle formation; propagating said recombinant adenoviral vector in a first type of complementing cells that expresses proteins from said first and from said second regions of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, infecting a culture of a second type of complementing cells with said recombinant adenovirus particles, wherein said second type of complementing cells express protein from said first region of the adenovirus genome, but not protein from said second region of the adenovirus genome, to produce the protein of interest; and harvesting the protein of interest.
  3. 17. A method for producing a protein of interest, the method comprising: infecting a culture of complementing cells with a recombinant adenoviral particle that has a genome comprising nucleic acid encoding the protein of interest under control of a promoter to produce the protein of interest, wherein said genome has deletions in a first region and in a second region, and each of the first and second regions is required for adenoviral genome replication and/or adenovirus particle formation, and wherein said complementing cells express protein from said first region of the genome of the adenoviral particle, but not protein from said second region of the genome of adenoviral particle, and harvesting the protein of interest.
  4. 19. A method for producing a protein of interest, the method comprising: infecting a culture of complementing cells with a recombinant adenoviral particle that has a genome comprising nucleic acid encoding the protein of interest under control of a promoter to produce the protein of interest, wherein said genome has deletions in a first region and in a second region, and each of the first and second regions is required for adenoviral genome replication and/or adenovirus particle formation, and wherein said complementing cells express protein from said first region of the genome of the adenoviral particle, but not protein from said second region of the genome of adenoviral particle, and harvesting the protein of interest, wherein said first region is El and wherein said second region is E2A.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4703008 Kiren-Amgen, Inc. Lin Oct 1987
US4835260 Genetics Institute, Inc. Shoemaker May 1989
US5047335 The Regents of the University of Calif. Paulson et al. Sep 1991
US5192539 Akzo N.V. Van Der Marel et al. Mar 1993
US5441868 Kirin-Amgen, Inc. Lin Aug 1995
US5457089 Behringwerke Aktiengesellschaft Fibi et al. Oct 1995
US5494790 Kyowa Hakko Kogyo Co., Ltd. Sasaki et al. Feb 1996
US5631158 Creative BioMolecules, Inc. Dorai et al. May 1997
US5767078 Johnson et al. Jun 1998
US5773569 Affymax Technologies N.V. Wrighton et al. Jun 1998
US5789247 Ballay et al. Aug 1998
US5830851 Affymax Technologies N.V. Wrighton et al. Nov 1998
US5835382 The Scripps Research Institute Wilson et al. Nov 1998
US5856298 Amgen Inc. Strickland Jan 1999
US5994128 IntroGene B.V. Fallaux et al. Nov 1999
US6033908 b.v. IntroGene Bout et al. Mar 2000
US6037453 Genentech, Inc. Jardieu et al. Mar 2000
US6475753 Human Genome Sciences, Inc. Ruben et al. Nov 2002
US6492169 Crucell Holland, B.V. Vogels et al. Dec 2002
US6558948 Kochanek et al. May 2003
US6653101 Alusuisse Holdings A.G. Cockett et al. Nov 2003
US6855544 Crucell Holland B.V. Hateboer et al. Feb 2005
US6878549 Introgene B.V. Vogels et al. Apr 2005
US20020116723 Grigliatti et al. Aug 2002
US20030087437 Asada et al. May 2003
US20030092160 Bout et al. May 2003

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP0185573INSTITUT PASTEURJun 1986
EP0411678GENETICS INSTITUTE, INC.Feb 1991
EP0833934INTROGENE BVApr 1998
WO199303163Feb 1993
WO199505465Feb 1995
WO199529994Nov 1995
WO199700326Jan 1997
WO199818926May 1998
WO199839411Sep 1998
WO199844141Oct 1998
WO199905268Feb 1999
WO199924068May 1999
WO200061164KENNETH S. WARREN LABORATORIESOct 2000
WO200063403INTROGENE B.V.Oct 2000
WO200138362CRUCELL HOLLAND B.V.May 2001
WO2002053580THE KENNETH S. WARREN INSTITUTE, INC.Jul 2002
WO2003038100CRUCELL HOLLAND B.V.May 2003
WO2003048197CRUCELL HOLLAND B.V.Jun 2003
WO2003048348CRUCELL HOLLAND B.V.Jun 2003
WO2003051927CRUCELL HOLLAND B.V.Jun 2003
WO2004003176THE KENNETH S. WARREN INSTITUTE, INC.Jan 2004
WO2004099396CRUCELL HOLLAND B.V.Nov 2004
WO2007134325INTROGEN THERAPEUTICS, INC.Nov 2007

Other Publications

Zhou et al. Journal of Virology, 1996, 70(10):7030-7038.*
#Alkhatib et al., “Expression of Bicistronic Measles Virus P/C mRNA by Using Hybrid Adenovirus: Levels of C Protein Synthesized In Vivo Are Unaffected by the Presence or Absence of the Upstream P Initiator Codon,” Journal of Virology, Nov. 1988, pp. 4059-4068, vol. 62, No. 11.
#Alkhatib et al., “High-Level Eurcaryotic In Vivo Expression of Biologically Active Measles Virus Hemagglutinin by Using an Adenovirus Type 5 Helper-Free Vector System,” Journal of Virology, Aug. 1988, pp. 2718-2727, vol. 62, No. 8.
#Berg et al., High-Level Expression of Secreted Proteins from Cells Adapted to Serum-Free Suspension Culture, Research Report, 1993, pp. 972-978, vol. 14, No. 6.
#Bout et al., “Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors,” Cancer Gene Therapy, 1996, pp. S24, vol. 3, No. 6.
#Bout et al., “Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6,” Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.
#Boutl et al., A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, vol. 4, No. 6.
#Brown et al., “Evaluation of Cell Line 293 for Virus isolation in Routine Viral Diagnosis,” Journal of Clinical Microbiology, Apr. 1986, pp. 704-708, vol. 23, No. 4.
#Bukreyev et al., “Recombinant Respiratory Syncytial Virus from Which the Entire SH Gene Has Been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,” Journal of Virology, Dec. 1997, pp. 8973-8982, vol. 71, No. 12.
#Caravokri et al., “Constitutive Episomal Expression of Polypeptide l X (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5,” Journal of Virology, Nov. 1995, pp. 6627-6633, vol. 69, No. 11.
#Carroll et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-179, vol. 3, No. 2.
#Ciccarone et al., “Lipofectamine 2000 Reagent for Transfection of Eukaryotic Cells,” Focus, 1999, pp. 54-55, vol. 21, No. 2.
#Cote et al., Serum-Free Production of Recombinant Proteins and Adenoviral Vectors by 293SF-3F6 Cells, Biotechnology and Bioengineering, Sep. 5, 1998, pp. 567-575, vol. 59, No. 5.
#Cronan, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, Jun. 25, 1990, pp. 10327-10333, vol. 265, No. 18.
#DuBridge et al., “Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System,” Molecular and Cellular Biology, Jan. 1987, pp. 397-387, vol. 7, No. 1.
#Endo et al., Growth of Influenza A Virus in Primary, Differentiated Epithelial Cells Derived from Adenoids, Journal of Virology, Mar. 1996, pp. 2055-2058, vol. 70, No. 3.
#European Search Report 05 10 0732, Apr. 7, 2005.
#Fallaux et al, “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Human Gene Therapy, Sep. 1, 1998, vol. 9, No. 1, pp. 1909-1917. Abstract.
#Fallaux et al., Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors, Human Gene Therapy, Jan. 20, 1996, pp. 215-222, vol. 7.
#Gallimore et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, vol. 6.
#Garnier et al. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells, Cytotechnology, 1994, pp. 145-155, vol. 15.
#GenBank Accession No. X02996.1, 1993, “Adenovirus type 5 left 32% of the genome.”
#Ghosh-Choudhury et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-1739, vol. 6, No. 6.
#Grabenhorst et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)G1cNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1- 4)G1cNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 718-725, vol. 232, No. 3, Berlin, Germany.
#Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol., 1977, pp. 59-72, vol. 36.
#Graham et al., “Growth of 293 cells in suspension culture,” J Gen Virol, Mar. 1987, pp. 937-940, vol. 68.
#Graham, Cell Lines, Promochem (visited Apr. 10, 2005) .
#Grand et al., “Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells,” Eur Mol Biol Organ J. 1986, 5 (6) 1253-1260. Abstract.
#Grand et al., “The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression,” Virology, 1995, vol. 210, No. 2, pp. 323-334. Abstract.
#Hollister et al., Stable expression of mammalian beta1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells, Glycobiology, 1998, pp. 473-480, vol. 8, No. 5, IRL Press, United Kingdom.
#Holzer et al., “Construction of a Vaccinia Virus Deficient in the Essential DNA Repair Enzyme Uracil DNA Glycosylase by a Complementing Cell Line,” Journal of Virology, Jul. 1997, pp. 4997-5002, vol. 71, No. 7.
#Inoue et al., Production of Recombinant Human Monoclonal Antibody Using ras-Amplified BHK-21 Cells in a Protein-free Medium, Biosci. Biotech. Biochem., 1996, pp. 811-817, vol. 60, No. 5.
#Interlocutory Decision of the Opposition Division of Jul. 21, 2003 in the case EP 0 695 351(European application 94 913 174.2).
#Jenkins et al., Getting the glycosylation right: Implications for the biotechnology industry, Nature Biotechnology, Aug. 1996, pp. 975-981, vol. 14, No. 8, Nature Publishing, US.
#Lopez et al., Efficient production of biologically active human recombinant proteins in human lymphoblastoid cells form integrative and episomal expression vectors, Gene, 1994, pp. 285-291, vol. 148.
#Louis et al., Cloning and Sequencing of the Cellular—Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-429, vol. 233.
#Lutz et al., “The Product of the Adenovirus Intermediate Gene IX Is a Transcriptional Activator,” Journal of Virology, Jul. 1997, pp. 5102-5109, vol. 71, No. 7.
#Manservigi et al., “Protection from Herpes Simplex Virus Type 1 Lethal and Latent Infections by Secreted Recombinant Glycoprotein B Constitutively Expressed in Human Cells with a BK Virus Episomal Vector,” Journal of Virology, Jan. 1990, pp. 431-436, vol. 64, No. 1.
#Massie et al., Improved Adenovirus Vector Provides Herpes Simplex Virus Ribonucleotide Reductase R1 and R2 Subunits Very Efficiently, Biotechnology, Jun. 1995, pp. 602-608, vol. 13.
#Merten et al., Production of Influenza Virus in Cell Cultures for Vaccine Preparation, Exp Med Biol., 1996, pp. 141-151, vol. 397.
#Minch et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialyltransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)G1c-N-AcR Linkages, Biotechnol. Prog., 1995, pp. 348-351, vol. 11, No. 3.
#Neumann et al., “Generation of influenza A viruses entirely from cloned cDNAs,” Proc. Natl. Acad. Sci., Aug. 1999, pp. 9345-9350, vol. 96.
#Opposition against European patent 1 108 787 B1 filed Oct. 5, 2005 in the name and on behalf of CEVEC Pharmaceuticals GmbH.
#Opposition against European patent 1 161 548 B1 filed Nov. 16, 2005, in the name and on behalf of CEVEC Pharmaceutical GmbH.
#Opposition against European patent 1108787 filed Oct. 5, 2005 in the name and on behalf of Probiogen AG.
#ORY et al., “A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes,” Proc. Natl. Acad. Sci., Oct. 1996, pp. 11400-11406, vol. 93.
#Pacitti et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-1415, vol. 61, No. 5, American Society for Microbiology.
#Parkinson et at., “Stable Expression of a Secretable Deletion Mutant of Recombinant Human Thrombomodulin in Mammalian Cells,” The Journal of Biological Chemistry, Jul. 25, 1990, pp. 12602-12610. vol. 265, No. 21.
#Pau et al., Abstract, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, Mar. 21, 2001, pp. 2716-2721, vol. 19, No. 17-19.
#Paul et al., Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines, Human Gene Therapy, 1993, pp. 609-615, vol. 4.
#Pazur et al., Abstract, Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies, Journal of Protein Chemistry, Nov. 2000, pp. 631-635, vol. 19, No. 8.
#PCT International Search Report, PCT/NL00/00247, dated Oct. 9, 2000, 3 pages.
#Pleschka et al., “A Plasmid-Based Reverse Genetics System for Influenza A Virus,” Journal of Virology, Jun. 1996, pp. 4188-4192, vol. 70, No. 6.
#PubMed listing of abstracts (visited Apr. 10, 2005)
#Reina et al., Comparison of Madin-Darby Canine Kidney cells (MDCK) with a Green Monkey Continuous Cell Line (Vero) and Human Lung Embryonated Cells (MRC-5) in the Isolation of Influenza A Virus from Nasopharyngeal Aspirates by Shell Vial Culture, Journal of Clinical Microbiology, Jul. 1997, pp. 1900-1901, vol. 35, No. 7.
#Rhim et al., “Development of Human Cell Lines from Multiple Organs,” Annals of the New York Academy of Sciences, 2000, pp. 16-25, vol. 919.
#Schiedner et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, 2000, Hum. Gene Ther. 11, 2105-2116.
#Setoguchi et al., “Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector,” Blood, Nov. 1, 1994, pp. 2946-2953, vol. 84, No. 9.
#Spector et al., “Regulation of Integrated Adenovirus Sequences During Adenovirus Infection of Transformed Cells,” Journal of Virology, Dec. 1980, pp. 860-871, vol. 36, No. 3.
#Stevens et al., “The N-Terminal Extension of the Influenza B Virus Nucleoprotein Is Not Required for Nuclear Accumulation or the Expression and Replication of a Model RNA,” Journal of Virology, Jun. 1998, pp. 5307-5312, vol. 72, No. 6.
#Stockwell et al., High-throughput screening of small molecules in Miniaturized Mammalian Cell-based Assays involving Post-translational Modifications, Chemistry and Biology, Feb. 1999, pp. 71-83, vol. 6, No. 2.
#U.S. Department of Health and Human Services, Public Health Service, Food and drug Administration, Center for Biologics Evaluation and Research, International Association for Biologicals, National Institute of Allergy and Infectious Diseases, National Vaccine Program Office, World Health Organization, Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development, Workshop, Friday, Sep. 10, 1999 (visited Sep. 30, 2005) .
#Weikert et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, Nature Biotechnology, Nov. 1999, pp. 1116-1121, vol. 17, No. 11, Nature Pub. Co., New York, NY, US.
#Yallop et al., “PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins,” Modern Biopharmaceuticals, Ed. J. Knablein, 2005, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
#Yan et al., Novel Asn-linked oligosaccharides terminating in Ga1NAcbeta(1-4)[Fucalpha(1-3)]G1cNAcbeta(1-.) are present in recombinant human Protein C expressed in human kidney 293 cells, Glycobiology, 1993, pp. 597-608, vol. 3. No. 6.
#Yeager et al., Constructing immortalized human cell lines, Current Opinion Biotechnology, 1999, pp. 465-469, vol. 10.
#Yu et al., “Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A,” Cancer Res., 1993, 53 (4) 891-8. Abstract.
#Zhang et al., Stable expression of human alpha-2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity, BBA—General Subjects, 1998, pp. 441-452, vol. 1425, No. 3, Elsevier Science Publishers, NL.
#Opposition against EP 1 161 548 filed with EPO on Oct. 8, 2007, 12 pages.
#Rhim, Johng S., Development of Human Cell Lines from Multiple Organs, Annals of the New York Academy of Sciences, 2000, pp. 16-25, vol. 919.
* cited by examiner

Referenced By

Document NumberAssigneeInventorsIssue/Pub Date
US7833753 Crucell Holland B.V. Dirk J. E. Opstelten et al. Nov 2010
US8097453 Crucell Holland B.V. Maria G. Pau et al. Jan 2012

Patent Family

The current document is not in a family.